1,314,229 Shares in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Purchased by BML Capital Management LLC

BML Capital Management LLC acquired a new position in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) during the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 1,314,229 shares of the company’s stock, valued at approximately $2,103,000. Reneo Pharmaceuticals accounts for 1.6% of BML Capital Management LLC’s investment portfolio, making the stock its 14th largest holding.

A number of other hedge funds have also added to or reduced their stakes in the stock. Dorsey Wright & Associates bought a new position in shares of Reneo Pharmaceuticals during the third quarter valued at approximately $28,000. Bank of New York Mellon Corp boosted its stake in shares of Reneo Pharmaceuticals by 13.1% during the third quarter. Bank of New York Mellon Corp now owns 35,963 shares of the company’s stock valued at $274,000 after purchasing an additional 4,165 shares in the last quarter. Barclays PLC lifted its position in Reneo Pharmaceuticals by 5.7% during the third quarter. Barclays PLC now owns 78,118 shares of the company’s stock valued at $595,000 after acquiring an additional 4,244 shares during the last quarter. Pale Fire Capital SE purchased a new stake in Reneo Pharmaceuticals during the third quarter valued at approximately $113,000. Finally, SG Americas Securities LLC purchased a new stake in Reneo Pharmaceuticals during the fourth quarter valued at approximately $35,000. 90.98% of the stock is currently owned by institutional investors.

Reneo Pharmaceuticals Price Performance

NASDAQ:RPHM opened at $1.68 on Wednesday. The firm has a 50 day moving average of $1.66 and a 200 day moving average of $3.52. Reneo Pharmaceuticals, Inc. has a 52 week low of $0.98 and a 52 week high of $10.98.

Reneo Pharmaceuticals (NASDAQ:RPHM) last posted its quarterly earnings results on Thursday, March 28th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.15). Equities research analysts anticipate that Reneo Pharmaceuticals, Inc. will post -0.85 EPS for the current year.

About Reneo Pharmaceuticals

Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.